StockData
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. (PCRX) stock

PCRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3028% above fair value
$36.48+0.00 (0.00%)

Close on Nov 17, 2026Market cap $1.45BP/E 104.2Yield –

Pacira BioSciences total assets

Total assets on the balance sheet at the end of each period.

Pacira BioSciences's total assets was $1.24B at Jun 30, 2026. For fiscal 2025 it was $1.26B, down 18.6% from the year before. Over ten years it grew 12.6% a year on average. The highest annual figure on record is $2.08B in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.26B-18.6%
FY2024Dec 31, 2024$1.55B-1.3%
FY2023Dec 31, 2023$1.57B-6.4%
FY2022Dec 31, 2022$1.68B-19.0%
FY2021Dec 31, 2021$2.08B+62.8%
FY2020Dec 31, 2020$1.27B+53.4%
FY2019Dec 31, 2019$831.07M+20.6%
FY2018Dec 31, 2018$689.35M+9.7%
FY2017Dec 31, 2017$628.37M+60.5%
FY2016Dec 31, 2016$391.47M+1.0%
FY2015Dec 31, 2015$387.74M+18.9%
FY2014Dec 31, 2014$326.07M+92.0%
FY2013Dec 31, 2013$169.82M+51.6%
FY2012Dec 31, 2012$112.05M-1.3%
FY2011Dec 31, 2011$113.49M+70.5%
FY2010Dec 31, 2010$66.56M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.24B-19.1%
Q1 FY2026Mar 31, 2026$1.21B-23.8%
Q4 FY2025Dec 31, 2025$1.26B-18.6%
Q3 FY2025Sep 30, 2025$1.30B-14.7%
Q2 FY2025Jun 30, 2025$1.54B-6.7%
Q1 FY2025Mar 31, 2025$1.59B+0.2%
Q4 FY2024Dec 31, 2024$1.55B-1.3%
Q3 FY2024Sep 30, 2024$1.52B-0.8%
Q2 FY2024Jun 30, 2024$1.65B+6.8%
Q1 FY2024Mar 31, 2024$1.58B+3.9%
Q4 FY2023Dec 31, 2023$1.57B-6.4%
Q3 FY2023Sep 30, 2023$1.53B-11.5%
Q2 FY2023Jun 30, 2023$1.54B-11.1%
Q1 FY2023Mar 31, 2023$1.52B-19.5%
Q4 FY2022Dec 31, 2022$1.68B-19.0%
Q3 FY2022Sep 30, 2022$1.73B+27.9%
Q2 FY2022Jun 30, 2022$1.73B+30.8%
Q1 FY2022Mar 31, 2022$1.89B+46.9%
Q4 FY2021Dec 31, 2021$2.08B+62.8%
Q3 FY2021Sep 30, 2021$1.36B+11.1%
Q2 FY2021Jun 30, 2021$1.33B+53.1%
Q1 FY2021Mar 31, 2021$1.29B+56.8%
Q4 FY2020Dec 31, 2020$1.27B+53.4%
Q3 FY2020Sep 30, 2020$1.22B+51.1%
Q2 FY2020Jun 30, 2020$866.11M+9.9%
Q1 FY2020Mar 31, 2020$821.38M+14.2%
Q4 FY2019Dec 31, 2019$831.07M+20.6%
Q3 FY2019Sep 30, 2019$807.49M+22.5%
Q2 FY2019Jun 30, 2019$787.84M+22.6%
Q1 FY2019Mar 31, 2019$719.16M+15.6%
Q4 FY2018Dec 31, 2018$689.35M+9.7%
Q3 FY2018Sep 30, 2018$659.05M+8.7%
Q2 FY2018Jun 30, 2018$642.68M+6.1%
Q1 FY2018Mar 31, 2018$622.04M+3.7%
Q4 FY2017Dec 31, 2017$628.37M+60.5%
Q3 FY2017Sep 30, 2017$606.09M+59.0%
Q2 FY2017Jun 30, 2017$605.75M–
Q1 FY2017Mar 31, 2017$599.96M–
Q4 FY2016Dec 31, 2016$391.47M–
Q3 FY2016Sep 30, 2016$381.15M–

More Pacira BioSciences figures

See a number that looks wrong?